Kornimate/medical-research-clean huggingface dataset:
antiphospholipid antibodies in patients of antiphospholipid syndrome (aps) with systemic lupus erythematosus (sle).

Conditions: Anti-phospholipid Antibobodies in Patients of SLE Presenting With Thrombosis or Pregnancy Complications

Summary: evaluation of antiphospholipid antibodies (apl) profile in systemic lupus erythematosus (sle) patients with obstetric and thrombotic complications. blood sample of the patients were taken for anti-beta-2-glycoprotein 1(anti-b2gpi), anticardiolipin (acl) and will be analyzed on alegria based on elisa.

antiphospholipid syndrome (aps) is characterized by presence of specific antiphospholipid antibodies (apl) with history of thrombosis and/or pregnancy morbidity. anti-phospholipid antibodies (apl) is a comprehensive antibody profile which includes lupus anticoagulant \[la\], anticardiolipin antibodies \[acl\], and/or anti-β2-glycoprotein-i antibodies \[aβ2gpi\]). a comprehensive antibody profile is needed for both diagnosis and classification of patients with aps, most significantly for the risk assessment of both pregnancy morbidity and thrombosis. double positivity (la, aβ2gpi or acl +) and triple positivity (la, aβ2gpi+, acl +) may have worse outcome and the patients with double and triple positivity may have recurrent thrombotic events. early detection of apl antibodies may avert patients with many complication associated with sle as well as from major thrombotic events because the detection of apl in sle has been proposed as a predictive and specific tool for the diagnosis of apls in sle. apl profile in sle patients with obstetric and thrombotic complications was analyzed, to see the association of different anti phospholipid antibodies with different clinical features of apls in sle patients.

Eligibility criteria:
inclusion criteria: diagnosed patients of sle presenting with thrombosis \& pregnancy complication were studied - exclusion criteria: * patients of sle without thrombosis

Keywords: apls, thrombosis, antiphosphoilipid antibodies
effects of group vs. home-based combined exercise-diet program in childhood obesity: a randomised controlled trial

Conditions: Obesity

Summary: the aim of this study was to compare the effect of a hospital group-based vs. home-based combined exercise-diet program for the treatment of childhood obesity.


Eligibility criteria:
inclusion criteria: * caucasian * overweight/obese exclusion criteria: * subjects with severe obesity (z-score above 2.5)

Keywords: children physical activity home-based treatment body mass index (z-bmi) percentage body fat waist circumference
long-term follow up of patients in the birmingham and lambeth liver evaluation strategies (ballets) study

Conditions: Fatty Liver; Liver Diseases

Summary: this study will follow-up a cohort of patients from the birmingham and lambeth liver evaluation strategies (ballets) study using a database search based on their individual national health service (nhs) numbers. the investigators will interrogate the hospital episode statistics database and the office of national statistics database, and examine three categories of end points: death, inpatient attendance primarily due to liver disease, and outpatient attendance primarily due to liver disease. a logistic regression analysis will then be conducted to determine associations between these end points and the presence, and degree, of fatty liver in the original ballets study, adjusted for age, sex, alcohol intake, bmi, and baseline alt measurement.

the birmingham and lambeth liver evaluation strategies (ballets) study was a prospective study of people in general practice who had an abnormal liver function test result. recruitment took place between 2005 and 2008, and patients were able to be grouped into four primary categories: hepato-cellular disease, hepato-biliary disease, tumour, non-specific with or without fatty liver. this study will focus on the fourth, non-specific, group of which there were 1,237 patients. this study will follow-up this cohort of patients using a database search based on their individual national health service (nhs) numbers. the investigators will interrogate the hospital episode statistics database (health outcomes) and the office of national statistics database (death), and examine three categories of end points: death, inpatient attendance primarily due to liver disease, and outpatient attendance primarily due to liver disease. deaths would be sub-categorised as including liver disease, or not. a logistic regression analysis will then be conducted to determine associations between these end points and the presence, and degree, of fatty liver in the original ballets study, with adjustment for age and sex. similar age- and sex-adjusted analyses will be conducted to investigate the association with other patient risk factors - alcohol intake and bmi. the analyses will be repeated incorporating an additional adjustment for baseline alanine aminotransferase (alt) measurement.

Eligibility criteria:
inclusion criteria: * adult with abnormal liver function test (lft) result exclusion criteria: * pre-existing or obvious liver disease
glucofriend-evaluation the effectiveness of glucobay when combined with a basal insulin

Conditions: Diabetes Mellitus

Summary: to evaluate the effectiveness of glucobay when combined with a basal insulin under daily-life treatment conditions in a large sample of korean patients.


Eligibility criteria:
inclusion criteria: * signed written informed consent * age ≥ 18 years * diagnosed of type 2 diabetes for at least 6 months prior to enrollment * patients treated with stable dose of a basal insulin (insulin glargine or insulin detemir) at least 2 months * hba1c≥7.5 and ≤10.0% exclusion criteria: * exclusion criteria must be read in conjunction with the local product information

Keywords: acarbose/glucobay® basal insulin ppg (postprandial glycaemia)
a study of the effects of canagliflozin on plasma volume in patients with type 2 diabetes mellitus

Conditions: Diabetes Mellitus, Type 2; Plasma Volume

Summary: the purpose of the study is to evaluate the effects of canagliflozin on plasma volume and renal parameters in patients with type 2 diabetes mellitus who are currently taking metformin and being treated for high blood pressure.

this is a double-blind (neither the patient or study staff will know the identity of the treatment assigned) in patients with type 2 diabetes mellitus (t2dm) who have inadequate glycemic (blood sugar) control on metformin monotherapy (metformin taken alone for control of t2dm) and who are currently being treated for hypertension (high blood pressure) with agents called angiotensin converting enzyme inhibitors (aceis) or angiotensin receptor blockers (arbs). in the study, patients will be randomized (assigned by chance) to receive treatment with canagliflozin or a placebo (a treatment identical in appearance to canagliflozin but does not contain active drug) for 12 weeks. during the 12-week treatment period, patients will also take metformin at a dose of at least 1500 mg/day in addition to their prescribed acei or arb for hypertension. patients will participate in the study for up to approximately 22 weeks.

Eligibility criteria:
inclusion criteria: * all patients must have a diagnosis of t2dm with inadequate glycemic control (ie, hba1c of \>=7.0% and \<=9.0% at screening) on metformin monotherapy and be receiving therapy with an antihypertensive agent (an acei or arb) for at least 4 weeks prior to screening exclusion criteria: -history of diabetic ketoacidosis, type 1 diabetes mellitus (t1dm), pancreas or beta cell transplantation, or diabetes secondary to pancreatitis or pancreatectomy; or a severe hypoglycemic episode within 6 months before screening

Keywords: diabetes mellitus, type 2 plasma volume canagliflozin metformin hemoglobin a1c hypertension angiotensin-converting enzyme inhibitors (aceis) angiotensin receptor blockers (arbs) pharmacodynamics pharmacokinetics
efficacy and safety of lx9211 in participants with postherpetic neuralgia

Conditions: Postherpetic Neuralgia

Summary: evaluation of the efficacy of lx9211 compared to placebo in reducing pain related to postherpetic neuralgia over an 11 week assessment period.


Eligibility criteria:
inclusion criteria: * participant has given written informed consent to participate in the study in accordance with local regulations * adult male and female participants ≥18 years of age at the time of screening * phn pain that is present for ≥3 months after healing of herpes zoster skin rash affecting a single dermatome (participants with more than 1 involved dermatome may also be included, provided the affected dermatomes are contiguous) * moderate to severe pain as confirmed by average pain score using scores recorded in the pain diary in the 14 days prior to randomization exclusion criteria: * presence of other painful conditions that may confound assessment or self-evaluation of phn * history of major depressive episode, active, significant psychiatric disorders * history of clinically significant drug or alcohol use disorder * phn affecting the face * use of opioid medications for management of phn within the 2 months prior to screening visit * use of non-steroidal anti-inflammatory drugs (nsaids) for the specific treatment of phn pain
evaluation of a decision support tool

Conditions: Medication Adherence; Hypertension; Decision Making, Shared; Patient-Centered Outcomes Research

Summary: investigators will conduct a randomized trial with patients, through one-on-one interviews, to evaluate their understanding of and willingness to use a decision support tool and to determine if receiving and discussing the decision support tool improves the likelihood that a patient is adherent to a new antihypertensive medication.


Eligibility criteria:
inclusion criteria: * does not pick up a prescription for a new antihypertensive medication within 14 days as identified by cvs pharmacy, their retail pharmacy provider. * high blood pressure diagnosis exclusion criteria: * under age 25.

Keywords: randomized controlled trial primary medication adherence decision-support tool patient-centered outcomes research antihypertensive medications one-on-one patient interviews
effect of laps-exendin on body weight in obese population

Conditions: Obesity

Summary: the purpose of this study is to determine the optimal dose and regimen of hm11260c, in combination with a hypocaloric diet, to reduce weight in obese subjects who are otherwise considered in stable health.

phase 2 study

Eligibility criteria:
1. inclusion criteria: * age: 18 years to 65 years * genders: male and female * healthy obese population * non-diabetes * stable body weight for at least 3 months prior to screening 2. exclusion criteria * pregnant or nursing (lactating) women * drug-induced obesity * diabetes mellitus (type 1, 2, and other) * previous surgical treatment for obesity * any known history of severe gastrointestinal (gi) disease or intolerance * known history of pancreatitis with presence of raised serum amylase and lipase * history of suicide attempts or recent history (within 2 years prior to screening) of major depression, anxiety, or other psychiatric disease requiring treatment with prescription medication including selective serotonin reuptake inhibitors (ssris), serotonin norepinephrine reuptake inhibitor s (snris), antipsychotics, and lithium.
prevention of post operative bone loss in children

Conditions: Osteoporosis; Cerebral Palsy; Spina Bifida; Osteopenia; Osteogenesis Imperfecta

Summary: hypothesis: one-dose pamidronate will prevent post-operative bone loss in children at risk for low bone density plan: children with chronic disease such as cp, spina bifida, etc. will be recruited pre operatively and studied with dxa scan. after surgery, children will be randomized to receive either pamidronate or saline. repeat dxa scan will determine bone lost after end of immobilization or nonweightbearing.

children at risk for post operative bone loss will be studied with preoperative dxa scan of spine and distal femora preoperative screening with standard labs electrolytes, ca++, po4, creatinine, vit d following surgery of hip(s) or lower extremities, randomization into treatment with low dose iv pamidronate (one dose) v placebo group repeat dxa scan after end of immobilization or non-weightbearing

Eligibility criteria:
inclusion criteria: * chronic condition predisposing to low bone density, such as cerebral palsy, osteogenesis imperfecta * lower extremity surgery proposed that will require post op nonweightbearing, casted or not, for a minimum of 4 weeks exclusion criteria: * creatinine \>1.2 * prior bisphosphonate exposure * orthopaedic implants in distal femoral precluding dxa scan * inability to cooperate with dxa scan

Keywords: pediatric osteoporosis pediatric osteopenia pamidronate post operative osteopenia
outcome of arterio-venous fistula for adult hemodialysis patients in assiut governorate

Conditions: Chronic Renal Failure

Summary: identification of the factors that affect the outcome of arteriovenous fistula in chronic renal failure patients that newly established regular dialysis in assiut governorate 1. to study the factors that influence the outcome of avf 2. to evaluate the vascular complications of avf as occlusion, rupture, aneurysmal dilation and hand ischemia


Eligibility criteria:
inclusion criteria: * all adult hemodialysis patients in assiut government are eligible for enrollment if they are newly dialyzed via avf and agree to participate in the study exclusion criteria: * patients are not dialyzed with avf
dental plaque microbiota in caries-free and caries-active children

Conditions: Caries; Plaque

Summary: dental caries is a polymicrobial infection originally thought to be caused by streptococcus mutans and lactobacilli. however, unprecedented developments in modern molecular techniques have demonstrated that several microbial species are associated with the disease in addition to streptococci and lactobacilli. dental caries initiation and progression is a dynamic process in which demineralization of the tooth structure, as a result of acid production from acidogenic bacteria (due to carbohydrate metabolism) is being counteracted by the remineralization of the tooth surface by strong alkali production by certain bacteria in the dental biofilm. the aim of the present study is to identify the different microbiota in the oral biofilm using new laboratory techniques as well as the levels of salivary proteins in caries-free compared with caries active arab children.

the objective of this study will be to investigate the dental plaque's microbial diversity using human oral microbe identification using next generation sequencing (homings) technology in the mixed dentition as well as the levels of salivary proteins in caries-free compared with caries active arab children. the study protocol was approved by the health science center ethical committee at kuwait university. one hundred 6-9 year-old children with caries active and caries-free status will be recruited from randomly selected public schools in kuwait. after dna purification from supragingival plaque samples, homings will be performed. to get an insight into the host factors involved in this complex interplay between the host and the bacteria, stimulated saliva from the study subjects will be analyzed by proteomics. for children in both groups supragingival plaque samples will be collected from the buccal and lingual surfaces of all teeth. after preparing the samples, the aliquots of purified dna samples will be shipped to the forsyth institute for human oral microbe identification using next generation sequencing (homings) protocol.

Eligibility criteria:
inclusion criteria: * arab 6-9 year old children * healthy * caries free, dmft/dmft=0 * caries active: dmft/dmft\>5 exclusion criteria: * children with a systemic disease or any drug use that could affect the microflora of the oral cavity or the salivary gland functions * history of salivary gland diseases * those who received antibiotic therapy during the last 3 months * children with severe localized or generalized periodontitis.
exploratory clinical trial of safety and efficacy of sacral nerve stimulation in patients with ulcerative colitis.

Conditions: Ulcerative Colitis

Summary: although the incidence of inflammatory bowel disease is stable in north american and european countries, the incidence of inflammatory bowel disease is increasing in newly industrialized countries, especially in china. the treatment drugs for ulcerative colitis include 5-aminosalicylic acid (5-asa), glucocorticoids, immunosuppressants, and biological agents. the aim of this exploratory clinical trial is to evaluate the safety and efficacy of sacral nerve stimulation in patients with ulcerative colitis.


Eligibility criteria:
inclusion criteria: * age 18-65 years * ulcerative colitis diagnosed for at least 3 mouths. * mayo score 6-12, mayo endoscopic score 2-3 points * resistant to medical treatment exclusion criteria: * treatment-naive ulcerative colitis (no previous treatment) * acute severe ulcerative colitis * currently taking any biologicals * previous surgical treatment or severe colitis at imminent risk of surgery * infective colitis * other systemic diseases * pregnancy and lactation

Keywords: ulcerative colitis sacral nerve stimulation
the efficacy of radiomics to predict tumor microenvironment markers and comprehensive therapy for bladder cancer

Conditions: Bladder Cancer; Radiomics; Immunotherapy

Summary: the aim of this study was to develop an radiomic model based on ct images to evaluate markers of the bladder cancer microenvironment, such as tsr,til, and ip. secondly, the association of the radiomic model with clinical outcomes and immunotherapy response was investigated.


Eligibility criteria:
inclusion criteria: 1. at least 18 years of age; 2. performing turb-t or rc during 2010-2022; 3. the primary lesion was located in the bladder, and the pathological diagnosis was urothelial carcinoma; 4. complete clinical information, pathological data, preoperative pelvic enhanced ct and follow-up records; exclusion criteria: 1. patients with distant metastasis; 2. combined with other malignant tumors or malignant tumor treatment history 3. malignant tumors of upper urinary tract; 4. clinical information, pathological data, preoperative pelvic enhanced ct and follow-up records were missing; 5. other situations in which the researcher considers it inappropriate to participate in this study.
chronic pancreatitis. effect of pioglitazone on endocrine function, exocrine function & structure, pain & life quality

Conditions: Chronic Pancreatitis; Insulin Resistance; Normal or Mildly Abnormal Stool Fat Levels

Summary: the purpose of this study is to determine if study drug (pioglitazone) treatment will improve pre-diabetes (insulin resistance) or ealy diabetes and improve clinical symptoms (pain) or laboratory evidence of chronic pancreatitis. the goal of the investigators is to gather information from this study to help gain understanding of a potential therapy for chronic pancreatitis.

the pancreas is a digestive organ that secretes insulin (and other hormones) into the blood for regulating blood sugar (glucose) and digestive enzymes into the intestine for digesting and absorbing nutrients consumed in meals. chronic pancreatitis is a progressive clinical disease of the pancreas, associated with swelling (inflammation), scarring (fibrosis) and loss of normal functioning tissue. patients develop diabetes mellitus (elevated blood sugar), malabsorption of nutrients, weight loss and pain. presently chronic pancreatitis is considered an irreversible condition because the mechanisms responsible for chronic pancreatitis are poorly understood and no therapy is proven. however, recent studies provide important clues that oral medications (thiazolidinediones) used to treat diabetes mellitus might improve or reverse features of chronic pancreatitis, including elevated sugar or diabetes, reduced secretion of digestive enzymes, and pancreatic swelling and scarring. note: takeda pharmaceuticals north america (tpna) provided pioglitazone and placebo pills with identically appearance until june 28, 2010, approximately the middle of the study.

Eligibility criteria:
inclusion criteria: * insulin resistance or mild diabetes mellitus * symptoms of abdominal pain * xray test showing damage to the pancreas * normal or mildly abnormal stool fat levels exclusion criteria: * mentally disabled patients * women who are planning pregnancy, pregnant or lactating/nursing * chronic pancreatitis is due to other specific conditions * autosomal dominant pancreatitis * classic cystic fibrosis with lung involvement * autoimmune pancreatitis * pancreatic cancer * biliary obstruction (non-pancreatic cause) * abdominal trauma * hypercalcemia * hypertriglyceridemia * surgical resection of the head of the pancreas * alcohol consumption within prior 2 months * specific medical conditions * gastric surgery * celiac sprue * crohns disease * heart failure * kidney failure * cirrhosis or liver disease * osteoporosis * blood clotting disorder * visual problems * low albumin * low bmi * specific medications \*diabetes drug treatment is allowed except for short-acting insulin, long-acting insule more than 15 units daily, pioglitazone, rosiglitazone, orlistat, acarbose, miglitol or voglibose.

Keywords: chronic pancreatitis insulin resistance